• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Progyny Strengthens Board of Directors with Appointment of Healthcare Leader and Advocate

    9/6/22 3:00:00 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care
    Get the next $PGNY alert in real time by email

    NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a leading benefits management company specializing in fertility and family building benefits solutions, today announced the appointment of a new member to its board of directors, effective August 30, 2022. Joining the board is Lloyd Dean, Chief Executive Emeritus and Founding Executive of CommonSpirit Health.

    "I am excited to welcome Lloyd to the Board and believe the value he brings from his experience on expanding access to healthcare will be an asset as we explore how we can further our reach when it comes to infertility and family building," said Pete Anevski, Chief Executive Officer of Progyny. "He brings complementary skills and experiences to the company that will help us continue on our path of high growth and industry leadership."

    Mr. Dean will serve on the Nominating and Corporate Governance Committee. Following this appointment, the Progyny Board now consists of ten directors.

    Mr. Dean brings to Progyny over 40 years of practice in improving health and expanding access to healthcare for all. As a Founding Executive of CommonSpirit Health, one of the nation's largest not-for-profit healthcare companies, Mr. Dean delivered on his vision of a healthcare system that uses innovative partnerships, modern technology, and human kindness so that more Americans can live in a healthier future. He was instrumental in creating CommonSpirit Health in February 2019, when Dignity Health and Catholic Health Initiatives combined to form one of the nation's leading providers of Medicaid and other healthcare services. Previously, he was CEO from 2019 to 2022, and prior to that, Mr. Dean was President and CEO of Dignity Health from 2012 to 2019, which grew under his leadership from a holding company into a dynamic healthcare enterprise.

    As an advocate for healthcare, Mr. Dean has served on many federal and state advisory panels and participated in regional and national charity and advocacy organizations. Since August 2015, Mr. Dean has also served on the board of directors of McDonald's Corporation. Additionally, Mr. Dean currently serves on the board of directors of Cal Poly State University Foundation, Carnegie Hall, CommonSpirit Health Foundation, Golden Arrow Merger Corp, and Guidehouse. Mr. Dean holds a Bachelor of Science in Sociology and a Master's in Education from Western Michigan University, an honorary Doctorate of Humane Letters from the University of San Francisco, and an honorary Doctor of Science degree from Morehouse School of Medicine, California State University and California Polytechnic State University.

    "I am honored to join a company that continues to deliver exceptional clinical outcomes, reduce healthcare spending for employers, and deliver an unparallel patient experience while expanding its footprint into other markets and industries," said Mr. Dean. "It's clear Progyny is the brand of choice for large employers when it comes to family building benefits, and I look forward to supporting its growth and value for all of its stakeholders."

    For more information visit www.progyny.com.

    About Progyny

    Progyny (NASDAQ:PGNY) is a leading fertility benefits management company. We are redefining fertility and family building benefits, proving that a comprehensive and inclusive solution can simultaneously benefit employers, patients, and physicians.

    Our benefits solution empowers patients with education and guidance from a dedicated Patient Care Advocate (PCA), provides access to a premier network of fertility specialists using the latest science and technologies, reduces healthcare costs for the nation's leading employers, and drives optimal clinical outcomes. We envision a world where anyone who wants to have a child can do so.

    Headquartered in New York City, Progyny has been recognized for its leadership and growth by CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Financial Times, INC. 5000, and Crain's Fast 50 for NYC. For more information, visit www.progyny.com.

    For Further Information, Please Contact:

    Investors:

    James Hart

    [email protected]



    Media:

    Selena Yang

    [email protected]



    Primary Logo

    Get the next $PGNY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PGNY

    DatePrice TargetRatingAnalyst
    12/2/2024$17.00Overweight → Neutral
    Analyst
    11/13/2024$26.00 → $19.00Buy → Hold
    Truist
    9/19/2024Mkt Outperform → Mkt Perform
    JMP Securities
    8/7/2024$37.00 → $24.00Buy → Hold
    Canaccord Genuity
    8/7/2024$31.00 → $25.00Outperform → Market Perform
    Leerink Partners
    8/7/2024Buy → Neutral
    BTIG Research
    7/16/2024$36.00Mkt Outperform
    JMP Securities
    5/10/2024Overweight → Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $PGNY
    SEC Filings

    See more
    • SEC Form 10-Q filed by Progyny Inc.

      10-Q - Progyny, Inc. (0001551306) (Filer)

      5/9/25 4:31:42 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Progyny, Inc. (0001551306) (Filer)

      5/8/25 4:22:47 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SCHEDULE 13G filed by Progyny Inc.

      SCHEDULE 13G - Progyny, Inc. (0001551306) (Subject)

      4/29/25 3:52:52 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Progyny downgraded by Analyst with a new price target

      Analyst downgraded Progyny from Overweight to Neutral and set a new price target of $17.00

      12/2/24 10:07:08 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny downgraded by Truist with a new price target

      Truist downgraded Progyny from Buy to Hold and set a new price target of $19.00 from $26.00 previously

      11/13/24 8:20:07 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny downgraded by JMP Securities

      JMP Securities downgraded Progyny from Mkt Outperform to Mkt Perform

      9/19/24 7:51:03 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Progyny, Inc. Announces First Quarter 2025 Results

      Reports Record Revenue of $324.0 Million, Reflecting 16.5% GrowthRaises Full Year Guidance Due to Strong Start to the YearEarly Selling Season Activity Reflects Ongoing Demand in Women's Health and Family Building Solutions NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended March 31, 2025 ("the first quarter of 2025") as compared to the three-month period ended March 31, 2024 ("the first quarter of 2024" or "the prior year period"). "We're pleased with the strong start to the year, highlighted by both our

      5/8/25 4:14:54 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny, Inc. Announces Details for Its First Quarter 2025 Results Report

      NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building, will report its financial results for the quarterly period ended March 31, 2025, after the close of the market on Thursday, May 8, 2025. The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcode. An audio repl

      4/24/25 2:49:33 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny Names Healthcare Veterans Melissa Cummings as Chief Operating Officer and Geoffrey Clapp as Chief Product Officer

      NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Progyny (NASDAQ:PGNY), a global leader in women's health and family building, today announced the appointments of Melissa Cummings as the company's first Chief Operating Officer (COO) and Geoffrey Clapp as its first Chief Product Officer (CPO). The additions to the executive leadership team will extend Progyny's ability to further drive operational excellence, advance innovation in product design and member experience, and continue to address care gaps and unmet needs across the spectrum of family building and women's health – from preconception to fertility and menopause. "Progyny has established itself at the forefront of building and del

      4/17/25 9:36:59 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Leadership Updates

    Live Leadership Updates

    See more

    $PGNY
    Financials

    Live finance-specific insights

    See more

    $PGNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $PGNY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $PGNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Progyny Names Healthcare Veterans Melissa Cummings as Chief Operating Officer and Geoffrey Clapp as Chief Product Officer

      NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Progyny (NASDAQ:PGNY), a global leader in women's health and family building, today announced the appointments of Melissa Cummings as the company's first Chief Operating Officer (COO) and Geoffrey Clapp as its first Chief Product Officer (CPO). The additions to the executive leadership team will extend Progyny's ability to further drive operational excellence, advance innovation in product design and member experience, and continue to address care gaps and unmet needs across the spectrum of family building and women's health – from preconception to fertility and menopause. "Progyny has established itself at the forefront of building and del

      4/17/25 9:36:59 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Bruker Appoints Laura Francis to its Board of Directors

      Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

      2/21/25 8:00:00 AM ET
      $BRKR
      $PGNY
      $SIBN
      $SWAV
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Misc Health and Biotechnology Services
      Health Care
    • Progyny, Inc. Enhances Suite of Services with Acquisition of BenefitBump

      NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, today announced the acquisition of BenefitBump, a comprehensive parental leave benefits navigation program for new and growing families. This addition enhances Progyny's fertility and family building offering, extending the company's ability to further serve the needs of families on their journey from pregnancy to early childhood and beyond. With 90% of parents seeking greater support to manage responsibilities at work and home, Progyny's enhanced suite of solutions aims to reduce member stress, improve recruitment, return-to-work and

      1/28/25 8:44:00 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny, Inc. Announces First Quarter 2025 Results

      Reports Record Revenue of $324.0 Million, Reflecting 16.5% GrowthRaises Full Year Guidance Due to Strong Start to the YearEarly Selling Season Activity Reflects Ongoing Demand in Women's Health and Family Building Solutions NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended March 31, 2025 ("the first quarter of 2025") as compared to the three-month period ended March 31, 2024 ("the first quarter of 2024" or "the prior year period"). "We're pleased with the strong start to the year, highlighted by both our

      5/8/25 4:14:54 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny, Inc. Announces Details for Its First Quarter 2025 Results Report

      NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building, will report its financial results for the quarterly period ended March 31, 2025, after the close of the market on Thursday, May 8, 2025. The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcode. An audio repl

      4/24/25 2:49:33 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny, Inc. Announces Fourth Quarter 2024 Results

      Reports Quarterly Revenue of $298.4 Million, Reflecting 10.6% GrowthGenerated $52.2 Million of Quarterly Operating Cash FlowIssues Financial Guidance for 2025, Reflecting Tenth Consecutive Year of Revenue Growth NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a transformative fertility, family building and women's health benefits solution, today announced its financial results for the three- and twelve-month periods ended December 31, 2024 ("the fourth quarter of 2024" and "the full year", respectively) as compared to the three- and twelve-month periods ended December 31, 2023 ("the fourth quarter of 2023" and "the prior year period",

      2/27/25 4:01:22 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Chief Operating Officer Cummings Melissa B was granted 41,667 shares (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      5/2/25 6:08:28 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 3 filed by new insider Cummings Melissa B

      3 - Progyny, Inc. (0001551306) (Issuer)

      5/2/25 6:01:18 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • New insider Clapp Geoffrey claimed ownership of 28,694 shares (SEC Form 3)

      3 - Progyny, Inc. (0001551306) (Issuer)

      5/2/25 6:00:23 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Executive Chairman Schlanger David J bought $2,202,330 worth of shares (150,000 units at $14.68), increasing direct ownership by 192% to 228,269 units (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      12/26/24 5:35:03 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • CHIEF EXECUTIVE OFFICER Anevski Peter bought $3,034,084 worth of shares (209,500 units at $14.48), increasing direct ownership by 90% to 441,463 units (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      12/26/24 5:31:32 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Progyny Inc.

      SC 13G/A - Progyny, Inc. (0001551306) (Subject)

      12/6/24 10:11:35 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Progyny Inc.

      SC 13G/A - Progyny, Inc. (0001551306) (Subject)

      11/14/24 4:31:23 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G/A filed by Progyny Inc. (Amendment)

      SC 13G/A - Progyny, Inc. (0001551306) (Subject)

      2/14/24 6:29:49 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care